Daxor’s blood volume analysis validated for COVID, sepsis patients

Daxor (DXR) highlighted the significant findings of a new pilot study published in the Journal of Critical Care. The research, titled, “Endothelial dysfunction in critically ill patients with sepsis and COVID-19 using the albumin transudation rate: A pilot study,” found that patients were often misclassified during clinical assessment, with many mistakenly believed to be “hypervolemic” when objective measurements showed them to be “hypovolemic,” and vice-versa. Key Findings from the Study: Pervasive Misdiagnosis: Clinicians frequently misjudged the total blood volume in patients suffering from COVID-19 or sepsis. Persistent Capillary Leakage: The study showed that “albumin transudation rate,” a measure of fluid leaking from blood vessels into tissues, was persistently elevated in both sepsis and COVID-19 patients throughout their ICU stay. Higher Leakage in Sepsis: Patients with sepsis exhibited significantly higher ATR than those with COVID-19, indicating a more severe and sustained breakdown in blood vessel integrity in sepsis, despite often having lower admission severity scores. Urgent Need for Better Tools: The study concludes there is a “frequent inaccuracy in clinical fluid status assessment, which demands more reliable diagnostic tools to better guide fluid therapy in critically ill patients”